



**Friday, April 28<sup>th</sup>**

3:00 – 4:00 PM	ITOG/ACCRU Meeting (9)	Phone Conference; Sanford Room
<b>4:00 – 6:00 PM</b>	<b>COMMITTEE MEETINGS</b>	
4:00 – 6:00 PM	Protocol Committee (15)	Phone conference; Duke University Room
4:30 – 6:00 PM	Correlative Science Committee (7)	Phone conference; Sanford Room
6:00 – 10:00 PM	Durham Bulls vs Buffalo Bisons (for non-ITOG board members)	Durham Bulls Athletic Park
6:30 – 9:30 PM	Board Meeting (with working dinner) (14)	Phone conference; Garden Room

**Saturday, April 29<sup>th</sup>**

6:45 – 7:30 AM	Breakfast	
7:20 – 7:30 AM	Welcome	Julie Ann Sosa & Ted Pappas
<b>7:30 – 9:45 AM</b>	<b>SESSION I: EPIDEMIOLOGY, CONTROVERSIES AND DEBATE</b>	
7:30 – 7:50 AM	Revising What We Think We Know About Thyroid Cancer Incidence & Mortality in the US	Cari Kitahara, NIH/NCI
7:50 – 8:10 AM	Exposure to Flame Retardant Chemicals and Risk for Papillary Thyroid Cancer	Heather Stapleton, Duke
8:10 – 8:30 AM	Medullary thyroid carcinoma registry: an essential tool in the study of a rare disease	Elizabeth Grubbs, MD Anderson
8:30 – 8:50 AM	The Use of Liquid Biopsy in the Management of Thyroid Cancer	Gilbert Cote, MD Anderson
8:50 – 9:30 AM	DEBATE: Genomic tumor interrogation in thyroid cancers: research tool, clinical too, or both?	Keith Bible, Mayo Clinic/Maria Cabanilla, MD Anderson
9:30 – 10:00 AM	Break	
<b>10:00 AM – 12:00 PM</b>	<b>SESSION II: SIGNALING</b>	
10:00 – 10:20 AM	Codon Bias, the Silent Secret of RAS Genes	Chris Counter, Duke
10:20 – 10:40 AM	Targeting MEK1/2 Kinases in Thyroid Cancer	Meng Meng Xu, Duke
10:40 – 11:00 AM	Targeting Notch for Medullary Thyroid Cancer	Herbert Chen, University of Alabama at Birmingham
11:00 – 11:20 AM	RCAN1-4/NFE2L3 pathway: a new regulatory pathway in cancer growth and metastases	Matthew Ringel, The Ohio State University
11:20 – 11:40 AM	Novel Insights into Thyroid Cancer Pathogenesis and Treatment from Genetic Models in Zebrafish	Yariv Houvras, Cornell
11:40 AM – 12:00 PM	Fly Therapeutics for RET Cancers	Ross Cagen, Icahn School of Medicine at Mount Sinai
12:00 – 2:00 PM	Working Lunch/ Business Meeting/Town Hall	
<b>2:00 – 4:00 PM</b>	<b>SESSION III: ADVANCED &amp; ANAPLASTIC THYROID CANCER</b>	
2:00 – 2:20 PM	Novel therapeutic dependencies of advanced thyroid cancers	James Fagin, Memorial Sloan Kettering
2:20 – 2:40 PM	Combining BRAF inhibitors and checkpoint inhibitors: What does it do to the tumor immune microenvironment?	Sareh Parangi, Massachusetts General Hospital
2:40 – 3:00 PM	Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors: data on SP600125, a novel molecule with a remarkable anticancer potential	Laura Fugazzola, University of Milan

3:00 – 3:20 PM	Randomized phase II study of paclitaxel/radiation therapy with or without pazopanib slurry: RTOG 0912	Eric J. Sherman, Memorial Sloan Kettering
3:20 – 3:40 PM	Targeted therapy plus atezolizumab (anti-PDL1) combinations in anaplastic and poorly differentiated thyroid cancer	Maria Cabanillas, MD Anderson
3:45 – 4:00 PM	Walk to Cameron Indoor Stadium	Georgia Beasley
4:00 – 6:00 PM	Tour Cameron Indoor Stadium (Group Photo)	
6:00 – 6:15 PM	Return to Washington Duke	
6:15 – 6:30 PM	Break	
6:30 – 9:30 PM	Dinner - “Immunotherapy Strategy with Recombinant Poliovirus”	Dr. Mathias Gromeier, Duke

### Sunday, April 30<sup>th</sup>

7:00 – 7:30 AM	Breakfast	
<b>7:30 – 9:30 AM</b>	<b>SESSION IV: CLINICAL TRIALS</b>	
7:30 – 7:50 AM	Fatigue in Thyroid Cancer	Anna Sawka, University Health Network
7:50 – 8:10 AM	Heterogeneity of Radioiodine Uptake and Differential Radiosensitivity on I-131 Therapeutic Efficacy	Sissy Jhiang, The Ohio State University
8:10 – 8:30 AM	Update on RAI Combination Trials and Concepts	Alan Ho, Memorial Sloan Kettering
8:30 – 8:50 AM	Phase I/II Trials of BRAF-inhibitors in DTC	Manisha Shah, The Ohio State University
8:50 – 9:10 AM	Phase 2 study of Regorafenib for second line treatment of metastatic progressive medullary thyroid cancer	Jochen Lorch, Dana-Farber Cancer Institute
9:10 – 9:30 AM	LOXO-RET-17001: The first in human trial	Lori Wirth, Massachusetts General Hospital
9:30 – 10:00 AM	Break/Hotel (check-out)/walk Al Buehler Trail	
<b>10:00 – 12:00 PM</b>	<b>SESSION V: SAVING THE BEST FOR LAST</b>	
10:00 – 10:20 AM	Combining immunotherapy with targeted therapy: The next steps for treatment of medullary thyroid cancer?	Ramona Dadu, MD Anderson
10:20 – 10:50 AM	Discovery-based bioinformatics-guided approaches to rational combination therapy in advance thyroid cancer	Bryan Haugen, University of Colorado at Denver
10:50 – 11:20 AM	Multidimensional Genomic Analysis of Thyroid Nodules	Richard Kloos & Giulia Kennedy, Veracyte
11:20 – 11:40 AM	Back by popular demand; the role of patient pressure and social media in advancing Bazedoxifene to the clinic for the treatment of breast cancer	Suzanne Wardell, Duke
11:40 AM – 12:00 PM	Excess frequency of pathogenic variants in the RET gene in population controls due to low penetrance alleles	Bruce Robinson, Kolling Institute of Medical Research
12:00 – 1:00 PM	Working Lunch/Closing Remarks	

## TALKS

**Saturday, April 29th**

### **SESSION I: EPIDEMIOLOGY, CONTROVERSIES AND DEBATE**

Cari Kitahara, NIH/NCI – Revising What We Think We Know About Thyroid Cancer Incidence & Mortality in the US

Heather Stapleton, Duke – Exposure to Flame Retardant Chemicals and Risk for Papillary Thyroid Cancer

Elizabeth Grubbs, MD Anderson – Medullary thyroid carcinoma registry: an essential tool in the study of a rare disease

Gilbert Cote, MD Anderson – The Use of Liquid Biopsy in the Management of Thyroid Cancer

Keith Bible, Mayo Clinic/Maria Cabanilla, MD Anderson – DEBATE: Genomic tumor interrogation in thyroid cancers: research tool, clinical too, or both?

### **SESSION II: SIGNALING**

Chris Counter, Duke – Codon Bias, the Silent Secret of RAS Genes

Meng Meng Xu, Duke – Targeting MEK1/2 Kinases in Thyroid Cancer

Herbert Chen, University of Alabama at Birmingham – Targeting Notch for Medullary Thyroid Cancer

Matthew Ringel, The Ohio State University – RCAN1-4/NFE2L3 pathway: a new regulatory pathway in cancer growth and metastases

Yariv Houvras, Cornell – Novel Insights into Thyroid Cancer Pathogenesis and Treatment from Genetic Models in Zebrafish

Ross Cagen, Icahn School of Medicine at Mount Sinai – Fly Therapeutics for RET Cancers

### **SESSION III: ADVANCED & ANAPLASTIC THYROID CANCER**

James Fagin, Memorial Sloan Kettering – Novel therapeutic dependencies of advanced thyroid cancers

Sareh Parangi, Massachusetts General Hospital – Combining BRAF inhibitors and checkpoint inhibitors: What does it do to the tumor immune microenvironment?

Laura Fugazzola, University of Milan – Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors: data on SP600125, a novel molecule with a remarkable anticancer potential

Eric J. Sherman, Memorial Sloan Kettering – Randomized phase II study of paclitaxel/radiation therapy with or without pazopanib slurry: RTOG 0912

Maria Cabanillas, MD Anderson – Targeted therapy plus atezolizumab (anti-PDL1) combinations in anaplastic and poorly differentiated thyroid cancer

### **Saturday Night Dinner:**

Mathias Gromeier, Duke – Immunotherapy Strategy with Recombinant Poliovirus

**Sunday, April 30<sup>th</sup>**

**SESSION IV: CLINICAL TRIALS**

Anna Sawka, University Health Network – Fatigue in Thyroid Cancer

Sissy Jhiang, The Ohio State University – Heterogeneity of Radioiodine Uptake and Differential Radiosensitivity on I-131  
Therapeutic Efficacy

Alan Ho, Memorial Sloan Kettering – Update on RAI Combination Trials and Concepts

Manisha Shah, The Ohio State University – Phase I/II Trials of BRAF-inhibitors in DTC

Jochen Lorch, Dana-Farber Cancer Institute – Phase 2 study of Regorafenib for second line treatment of metastatic  
progressive medullary thyroid cancer

Lori Wirth, Massachusetts General Hospital – LOXO-RET-17001: The first in human trial

**SESSION V: SAVING THE BEST FOR LAST**

Ramona Dadu, MD Anderson – Combining immunotherapy with targeted therapy: The next steps for treatment of  
medullary thyroid cancer?

Bryan Haugen, University of Colorado at Denver – Discovery-based bioinformatics-guided approaches to rational  
combination therapy in advance thyroid cancer

Richard Kloos & Giulia Kennedy, Veracyte, Inc. – Multidimensional Genomic Analysis of Thyroid Nodules

Suzanne Wardell, Duke – Back by popular demand; the role of patient pressure and social media in advancing  
Bazedoxifene to the clinic for the treatment of breast cancer

Bruce Robinson, Kolling Institute of Medical Research – Excess frequency of pathogenic variants in the RET gene in  
population controls due to low penetrance alleles